Skip to main content

Jaguar Health, Inc.

JAGX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001585608

No open-market purchases or sales by Jaguar Health, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $15.9K in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, −3 vs. previous quarter
8
13F valueReported value at the end of Q2 2026
$15.9K
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding JAGX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding JAGX at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Jaguar Health, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 2, 2025 (view filing)Mar 312 daysMicek JohnDirectorPPurchase+18.0K$50,000.00+$450.0M–9.00K afterDerivative2 lotsPrice outlierDuplicate filing
Apr 2, 2025 (view filing)Mar 312 daysKing Steven R.See RemarksPPurchase+7.20K$20,000.00+$72.0M–3.60K afterDerivative2 lotsPrice outlier
Apr 2, 2025 (view filing)Mar 312 daysSiegel Jonathan B.DirectorPPurchase+18.0K$50,000.00+$450.0M–9.00K afterDerivative2 lotsPrice outlierDuplicate filing
Apr 2, 2025 (view filing)Mar 312 daysConte Lisa ACEO and PresidentPPurchase+18.0K$50,000.00+$450.0M–9.00K afterDerivative2 lotsPrice outlier
Apr 2, 2025 (view filing)Mar 312 daysChaturvedi Pravin RChief Scientific OfficerPPurchase+7.20K$20,000.00+$72.0M–3.60K afterDerivative2 lotsPrice outlier
Apr 2, 2025 (view filing)Mar 312 daysBochnowski James JDirectorPPurchase+54.0K$150,000.00+$4.05B–27.0K afterDerivative2 lotsPrice outlier
Apr 2, 2025 (view filing)Mar 312 daysWolin Jonathan S.See RemarksPPurchase+18.0K$50,000.00+$450.0M–9.00K afterDerivative2 lotsPrice outlier
Apr 2, 2025 (view filing)Mar 312 daysLizak Carol R.Chief Financial OfficerPPurchase+10.8K$30,000.00+$162.0M–5.40K afterDerivative2 lotsPrice outlier
Jan 3, 2023 (view filing)5:03 PM ETDec 31, 20223 daysWolin Jonathan S.Chief of Staff, CCO & GCPPurchase+317$0.03+$9.51+4.8%6.98K after
Mar 30, 2022 (view filing)Sep 13, 2021198 daysLateLizak Carol R.Chief Financial OfficerPPurchase+7.97K$2.51+$20.0KNew position7.97K after

Top 10 13F holders, Q2 2026

The largest institutional positions in Jaguar Health, Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 8 holders
Institutions holding JAGX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
UBS Group AG4,000$12.0K0.00%−108,906−96.5%Reduced
Tower Research Capital LLC (TRC)1,160$3.48K0.00%−1,151−49.8%Reduced
SBI Securities Co., Ltd.84$2520.00%−2,487−96.7%Reduced
Barclays PLC56$1680.00%+56New
Wells Fargo & Company5$150.00%−195−97.5%Reduced
Leonteq Securities AG5$150.00%−183−97.3%Reduced
International Assets Investment Management, LLC1$30.00%−44−97.8%Reduced
Royal Bank of Canada20$00.00%−682−97.2%Reduced